Switch theme
Sign up to access all valuation multiples
Pacific Shuanglin Bio-pharmacy Co Ltd is engaged in the research, development, production, and marketing of blood products.
1993
2.8K+
LTM Revenue $427M
LTM EBITDA $146M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pacific Shuanglin has a last 12-month revenue of $427M and a last 12-month EBITDA of $146M.
In the most recent fiscal year, Pacific Shuanglin achieved revenue of $321M and an EBITDA of $116M.
Pacific Shuanglin expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pacific Shuanglin valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $321M | $408M | XXX | XXX | XXX |
| Gross Profit | $125M | $173M | XXX | XXX | XXX |
| Gross Margin | 39% | 42% | XXX | XXX | XXX |
| EBITDA | $116M | $139M | XXX | XXX | XXX |
| EBITDA Margin | 36% | 34% | XXX | XXX | XXX |
| Net Profit | $53.9M | $80.9M | XXX | XXX | XXX |
| Net Margin | 17% | 20% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Pacific Shuanglin's stock price is CNY 24 (or $3).
Pacific Shuanglin has current market cap of CNY 17.7B (or $2.4B), and EV of CNY 16.6B (or $2.3B).
See Pacific Shuanglin trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $2.4B | XXX | XXX | XXX | XXX | $0.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Pacific Shuanglin has market cap of $2.4B and EV of $2.3B.
Pacific Shuanglin's trades at 5.4x LTM EV/Revenue multiple, and 15.6x LTM EBITDA.
Analysts estimate Pacific Shuanglin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Pacific Shuanglin and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.3B | XXX | XXX | XXX |
| EV/Revenue | 5.6x | XXX | XXX | XXX |
| EV/EBITDA | 16.4x | XXX | XXX | XXX |
| P/E | 23.0x | XXX | XXX | XXX |
| P/E/Growth | 1.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPacific Shuanglin's NTM/LTM revenue growth is 16%
Pacific Shuanglin's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $27K for the same period.
Over next 12 months, Pacific Shuanglin's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Pacific Shuanglin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Pacific Shuanglin and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 27% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 50% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $27K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 24% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pacific Shuanglin acquired XXX companies to date.
Last acquisition by Pacific Shuanglin was XXXXXXXX, XXXXX XXXXX XXXXXX . Pacific Shuanglin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Pacific Shuanglin founded? | Pacific Shuanglin was founded in 1993. |
| Where is Pacific Shuanglin headquartered? | Pacific Shuanglin is headquartered in China. |
| How many employees does Pacific Shuanglin have? | As of today, Pacific Shuanglin has 2.8K+ employees. |
| Is Pacific Shuanglin publicy listed? | Yes, Pacific Shuanglin is a public company listed on SHE. |
| What is the stock symbol of Pacific Shuanglin? | Pacific Shuanglin trades under 000403 ticker. |
| When did Pacific Shuanglin go public? | Pacific Shuanglin went public in 1996. |
| Who are competitors of Pacific Shuanglin? | Similar companies to Pacific Shuanglin include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Pacific Shuanglin? | Pacific Shuanglin's current market cap is $2.4B |
| What is the current revenue of Pacific Shuanglin? | Pacific Shuanglin's last 12-month revenue is $427M. |
| What is the current EBITDA of Pacific Shuanglin? | Pacific Shuanglin's last 12-month EBITDA is $146M. |
| What is the current EV/Revenue multiple of Pacific Shuanglin? | Current revenue multiple of Pacific Shuanglin is 5.4x. |
| What is the current EV/EBITDA multiple of Pacific Shuanglin? | Current EBITDA multiple of Pacific Shuanglin is 15.6x. |
| What is the current revenue growth of Pacific Shuanglin? | Pacific Shuanglin revenue growth between 2023 and 2024 was 27%. |
| Is Pacific Shuanglin profitable? | Yes, Pacific Shuanglin is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
